Netherlands· NL-20df7092474a
Inaqovi 35 mg/100, fimomhulde tabletten
A decitabin, kombinationen product containing cedazuridine + decitabine, registered in Netherlands by Otsuka Pharmaceutical Netherlands B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Decitabin, kombinationen is registered in 10 of 19 countries.
Countries holding a registration under ATC L01BC58 (decitabin, kombinationen), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Decitabin, kombinationen · ATC L01BC58
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CEDAZURIDINE + DECITABINE
- Manufacturer
- Otsuka Pharmaceutical Netherlands B.V.
- Country
- Netherlands (NL)
- ATC code
- L01BC58
- ATC class
- Decitabin, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1756
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Decitabin, kombinationen in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaINQOVITAIHO PHARMA CANADA, INC.
- CzechiaINAQOVIOtsuka Pharmaceutical Netherlands B.V., Amsterdam
- SpainINAQOVI 35 MG/100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAOtsuka Pharmaceutical Netherlands B.V.
- FinlandInaqoviOtsuka Pharmaceutical Netherlands B.V.
- United KingdomInaqovi 35mg/100mg tabletsOtsuka Pharmaceuticals (U.K.) Ltd
- IrelandInaqovi 35 mg/100 mg film-coated tabletsOtsuka Pharmaceutical Netherlands B.V.
- IcelandInaqoviOtsuka Pharmaceutical Netherlands B.V.*
- NorwayInaqoviOtsuka Pharmaceutical Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inaqovi
- Liechtenstein · Inaqovi
- Norway · Inaqovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7e1b730a-625b-484e-b411-1a8f00794e0d GET /v1/drugs/7e1b730a-625b-484e-b411-1a8f00794e0d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/inaqovi-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Decitabine, combinations",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130289",
"excipients": [
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL (E 1203)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"CEDAZURIDINE",
"DECITABINE"
],
"leaflet_url": null,
"authorised_at": "2023/09/15",
"procedure_number": "EMEA/H/C/005823",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1756",
"additional_monitoring": "Y"
}See everything about decitabin, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.